Elderberry Functional Gum and Cognitive & Oral Health in Older Adults
A legfontosabb adatok
- Ki végzi
- Burdur Mehmet Akif Ersoy University
- Hol
- Törökország1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Résztvevők
- 34 fő, tervezett
- Kezdés
- 2025. nov. 1.
- Tervezett befejezés
- 2026. nov. 1.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Elderberry Anthocyanin Chewing Gum
- Placebo Chewing Gum
- A regiszteradat frissítve
- 2025. július 8.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for older adults with mildly reduced memory and thinking. It tests an elderberry chewing gum against a gum without the active ingredient.
- Életkor
- The criteria say 60 and over; the record's minimum age is 65 Years.
- Nem
- All sexes can join.
- A betegség stádiuma
- Mildly reduced thinking ability, with a MoCA test score of 20-25. Other long-term diseases must be stable, for example high blood pressure or controlled diabetes.
- Korábbi kezelés
- No probiotics, prebiotics or antibiotics in the last three months. No antiseptic mouthwashes that could strongly affect mouth bacteria. Regular medicines are allowed.
- Biomarker vagy leletérték
- MoCA score 20-25.
A részvétel fő kizáró okai
- Moderate to severe dementia (MoCA < 20)
- Active infection or a whole-body inflammatory disease
- Jaw joint problems that make chewing gum hard
- Smokers, or people without good teeth (fewer than 20 natural teeth, unless a working denture lets them chew without problems)
- Known allergy to elderberry or its parts
A regiszter feltételei, szó szerint
Mind a 11 feltétel megnézéseKevesebb
Ki vehet részt
- Individuals aged 60 and over
- Individuals with mildly reduced cognitive function using the MoCA test (MoCA score: 20-25)
- Those with stable systemic diseases (e.g. HT, controlled DM)
- Those with adequate dental health (≥20 natural teeth or no chewing problems with functional prosthesis)
- Non-smokers and those who use regular medication and do not use antibiotics or antiseptic mouthwashes that could seriously affect the oral microbiota
- Individuals who are willing to participate in the study and can give written consent
Ki nem vehet részt
- Moderate to severe dementia (MoCA < 20)
- Presence of active infection or systemic inflammatory disease
- Temporomandibular joint disorders affecting gum chewing function
- Known allergy to elderberry or its components
- Use of probiotics, prebiotics, or antibiotics within the last three months
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Globally, the aging population is increasing rapidly, leading to a dramatic rise in the prevalence of Alzheimer's disease and other types of dementia. Neurodegenerative disorders are characterized by pathological hallmarks such as β-amyloid (Aβ) plaque accumulation, tau protein aggregation, synaptic loss, and widespread neuroinflammation. These processes impair key cognitive domains including attention, memory, executive function, and orientation, hindering independent daily functioning.
A teljes eredeti leírásKevesebb
Beyond cognitive decline, neurodegenerative diseases are associated with a marked deterioration in oromotor functions, such as chewing and swallowing. Mastication plays a critical role not only in digestion but also in neuro-sensory stimulation. Trigeminal nerve signaling activated by chewing enhances neurotransmitter release, boosts neurotrophic factor production (e.g., BDNF), and facilitates Aβ clearance, thereby supporting synaptic plasticity and reducing inflammation. Neuroimaging studies have shown that a higher number of functional occlusal pairs is associated with increased gray and white matter volume in regions affected early in Alzheimer's disease.
Systematic reviews have identified poor mastication and tooth loss as risk factors for cognitive decline and dementia. Mechanistically, loss of afferent input from the oral cavity-due to tooth loss, reduced chewing force, prosthetic use, or muscle atrophy-leads to reduced brain stimulation, diminished neurotrophic support, and impaired cerebral blood flow. Thus, geriatric-friendly chewing gum formulations with low elasticity and ease of chewing have been recommended.
Chewing gum is a promising vehicle for functional compounds due to its potential for transmucosal absorption and cognitive stimulation. Randomized controlled trials have shown that both active and inactive gums improve attention and reduce error rates in cognitive tasks, highlighting the beneficial effects of mastication.
Another emerging target for cognitive enhancement is the oral microbiota, a complex ecosystem of over 700 bacterial species. Dysbiosis in this ecosystem has been linked to neurological outcomes via inflammatory and neurotoxic pathways. Certain pathogens, such as Porphyromonas gingivalis, have been detected in the brains of Alzheimer's patients. Moreover, metagenomic studies have shown that reduced salivary microbial diversity correlates with poorer cognitive performance, even in young adults.
Elderberry (Sambucus nigra L.) is rich in anthocyanins (e.g., cyanidin-3-glucoside, cyanidin-3-sambubioside) with strong antioxidant and anti-inflammatory properties. Literature shows that polyphenols can be absorbed via buccal and sublingual mucosa, bypassing first-pass metabolism and providing faster systemic effects. However, the impact of anthocyanin-enriched chewing gum on oral microbiota and cognitive function has not yet been systematically investigated.
This study aims to develop and evaluate a geriatric-friendly functional chewing gum enriched with standardized elderberry anthocyanins. The intervention targets dual mechanisms-neurophysiological and microbial-to support cognitive health and balance oral microbiota in older adults.
A vizsgálat 2 csoportja
- Elderberry Chewing Gum GroupA vizsgált kezelés
Participants receive chewing gum containing standardized elderberry anthocyanins twice daily for 6 weeks
Kezelés: Elderberry Anthocyanin Chewing Gum
- Placebo Arm TitlePlacebo, összehasonlításként
Participants receive anthocyanin-free chewing gum matched in appearance and taste, twice daily for 6 weeks
Kezelés: Placebo Chewing Gum
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Evaluation of the Effects of Elderberry-Based Anthocyanin-Enriched Functional Chewing Gum on Cognitive Functions and Oral Microbiota in Older Adults: A Double-Blind, Randomized Controlled Trial
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- A regiszteradat frissítve
- 2025. július 8.